# Lonza

Source: https://onco.cc/companies/lonza/  
OnCo record `lonza` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lonza is the largest contract manufacturer for biologics, ADCs, and cell therapies, and owns the Synaffix ADC linker technology and the Cocoon cell-manufacturing platform.

## Summary

Lonza, based in Basel and listed as LONN.SW, is the largest contract manufacturer for biologics, antibody-drug conjugates and cell therapies, and it owns the Synaffix ADC linker technology and the Cocoon cell-manufacturing platform. It is a Swiss CDMO with bioconjugation capacity in Visp, mammalian manufacturing worldwide including the former Genentech Vacaville site acquired in 2024, cell and gene therapy sites in Houston and Geleen, and the Cocoon closed platform. OnCo links it to ADC bioconjugation, closed automated cell-therapy manufacturing, viral vector manufacturing, sterile fill-finish and payload-linker synthesis, to Synaffix, and to the CDMO term. Whether contract manufacturing capacity, rather than science, becomes the limiting factor for ADCs and cell therapies is the question its position raises. Synaffix has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-08
- Tags: supporting
- HQ: Basel
- Type: cro-services
- Website: https://www.lonza.com
- Ticker: LONN.SW

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Lonza_Group
- Official website: https://www.lonza.com

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [ADC bioconjugation manufacturing (CDMOs)](https://onco.cc/technologies/adc-cdmo-manufacturing/), [Antibody manufacturing (CHO bioprocessing)](https://onco.cc/technologies/monoclonal-antibody-manufacturing/), [Autologous CAR-T manufacturing, batch by batch](https://onco.cc/technologies/car-t-manufacturing-process/), [Closed automated cell-therapy manufacturing](https://onco.cc/technologies/closed-automated-cell-manufacturing/), [Downstream purification (Protein A capture, viral clearance, polishing)](https://onco.cc/technologies/downstream-purification-chromatography/), [GMP, inspections, Form 483s and warning letters](https://onco.cc/technologies/pharmaceutical-gmp-inspections/), [mRNA and lipid nanoparticle manufacturing](https://onco.cc/technologies/mrna-lnp-manufacturing/), [Payload-linker synthesis (high-potency API)](https://onco.cc/technologies/high-potency-payload-synthesis/), [Small-molecule API synthesis](https://onco.cc/technologies/small-molecule-api-synthesis/), [Sterile fill-finish and lyophilisation](https://onco.cc/technologies/sterile-fill-finish/), [The ADC supply chain (antibody, payload-linker, conjugation, fill)](https://onco.cc/technologies/adc-supply-chain/), [Viral vector manufacturing (lentiviral, retroviral, AAV)](https://onco.cc/technologies/viral-vector-manufacturing/)
- companies: [Synaffix (Lonza)](https://onco.cc/companies/synaffix/)
- terms: [CDMO (contract development and manufacturing organisation)](https://onco.cc/terms/cdmo/)

---
JSON: https://onco.cc/api/v1/entities/lonza.json